search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Infection prevention


because in hospital data the absence of a test may itself encode clinical judgement rather than simple data loss. These principles are consistent with the recommendations emerging from recent reviews of automated surveillance and infection-prediction systems. Pathogen-specific data design is also necessary. CDI models often use prior and current antibiotic exposure, acid-suppressive therapy, previous CDI, age, renal function, ward movement and local CDI pressure. MRSA and MSSA risk models benefit from variables such as prior colonisation, wound burden, central- line exposure and ICU stay. For Gram-negative bacteraemia, urinary-source proxies, catheter exposure, urological procedures and prior resistant isolates become more relevant. SSI surveillance requires post-procedural longitudinal data, including readmissions and, for implant surgery, longer follow-up windows.15 This approach argues against generic “one- size-fits-all” infection models and in favour of carefully scoped pathogen or syndrome models.


Interpreting AI outputs Explainability is critical in IPC because the output of a model should not merely indicate high risk; it should support an actionable clinical or operational response. Recent reviews have identified explainable AI approaches, including SHAP analyses, as important for building clinician trust and translating models into decisions (SHapley Additive exPlanations is a game-theoretic approach used to explain the predictions of machine learning models).16


AMR forecasting study from UKHSA, feature- importance analysis revealed that predictions were influenced not only by prior resistance in the same pathogen-antibiotic pair but also by wider antibiotic-use patterns and resistance relationships across organisms. That kind of explanation can directly inform stewardship planning. A practical way to interpret AI in IPC is to define outputs at three levels: patient-level action, ward-level action and trust-level action. Patient-level outputs may prompt isolation, review of central lines or urinary catheters, earlier stool testing, escalation to microbiology or a focused antimicrobial review. Ward-level outputs may support environmental cleaning escalation, hand-hygiene auditing or device- bundle review. Trust-level outputs can inform


stewardship policy, target setting and resource allocation. Without such response pathways, even highly accurate models risk becoming passive dashboards rather than active IPC tools. Threshold selection is equally important. Low


thresholds may identify more true positives but generate unacceptable false-alert burdens; high thresholds may improve specificity but limit sensitivity in early prevention. CDI is a useful example: systematic reviews note that machine-learning models can show reasonable discrimination but still struggle with positive predictive. value in low-incidence settings, making workflow design and selective intervention crucial17


AI is therefore best


conceptualised as a prioritisation tool rather than an autonomous decision-maker.


In the


Measuring improvement and assessing effectiveness For NHS deployment, evaluation must move beyond model accuracy. Four types of metrics are required. Model metrics include discrimination, calibration, false-alert rates and lead time. Process metrics include time to isolation, completion of stewardship review, device days, adherence to hand- hygiene prompts and environmental cleaning compliance. Clinical outcome metrics include hospital-onset infection rates, recurrence, attributable mortality, length of stay and readmission. Operational and economic metrics include bed-days released, staff time saved and cost avoided. This aligns with both UK surveillance practice and broader hospital-IPC implementation science.


Data quality is central to trustworthy AI, particularly in IPC where outputs can lead to isolation, antibiotic changes, device removal or environmental escalation.


Study design is critical since reliable


evaluation requires interrupted time series, stepped-wedge designs or prospective controlled before–after studies wherever feasible. Simple pre/post comparisons can be misleading because HCAI rates are influenced by seasonality, occupancy, diagnostic intensity and case mix.18


England’s long-standing surveillance


datasets and contractual thresholds are a major advantage here because they offer stable baselines and established reporting structures for Trust-level comparison.


Pathogens and measurable improvements The most important conclusion regarding pathogen-specific reduction is that UK evidence remains limited. National surveillance clearly demonstrates persistent or increasing burdens for CDI, MRSA and several Gram-negative bloodstream infections, but published UK studies showing that AI interventions have already reduced these infections at trust level are currently sparse.19


The present UK evidence


base is stronger for implementation readiness and data infrastructure than for demonstrated pathogen reduction. Internationally, the most informative real- world example concerns CDI. A prospective quality-improvement study at Michigan Medicine evaluated an AI-guided infection- prevention bundle targeted at patients at high CDI risk. The intervention did not significantly reduce CDI incidence, but it did reduce use of high-risk antimicrobials including piperacillin- tazobactam and clindamycin, particularly among patients flagged by the model.20


This suggests


that AI may first demonstrate value through stewardship-sensitive process improvements before infection-incidence reductions become detectable. For hand hygiene, the evidence shows stronger gains in measurement fidelity than


September 2026 I www.clinicalservicesjournal.com 21


Paulista - stock.adobe.com


t


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85